25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Cellumed Co. Ltd
Buy, Hold or Sell?

Let's analyze Cellumed together

I guess you are interested in Cellumed Co. Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cellumed Co. Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cellumed Co. Ltd

I send you an email if I find something interesting about Cellumed Co. Ltd.

1. Quick Overview

1.1. Quick analysis of Cellumed (30 sec.)










1.2. What can you expect buying and holding a share of Cellumed? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
12.8%

What is your share worth?

Current worth
₩611.95
Expected worth in 1 year
₩260.08
How sure are you?
56.4%

+ What do you gain per year?

Total Gains per Share
₩-351.87
Return On Investment
-15.9%

For what price can you sell your share?

Current Price per Share
₩2,215.00
Expected price per share
₩1,922 - ₩3,385
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cellumed (5 min.)




Live pricePrice per Share (EOD)
₩2,215.00

2.2. Growth of Cellumed (5 min.)




Is Cellumed growing?

Current yearPrevious yearGrowGrow %
How rich?$21.5m$36.1m-$12.8m-54.9%

How much money is Cellumed making?

Current yearPrevious yearGrowGrow %
Making money-$5.2m-$3.4m-$1.8m-34.5%
Net Profit Margin-27.5%-21.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Cellumed (5 min.)




2.4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)




  Industry Rankings (Medical Instruments & Supplies)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cellumed?

Welcome investor! Cellumed's management wants to use your money to grow the business. In return you get a share of Cellumed.

First you should know what it really means to hold a share of Cellumed. And how you can make/lose money.

Speculation

The Price per Share of Cellumed is ₩2,215. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cellumed.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cellumed, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩611.95. Based on the TTM, the Book Value Change Per Share is ₩-87.97 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-14.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cellumed.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.040.0%-0.110.0%-0.070.0%-0.030.0%-0.020.0%
Usd Book Value Change Per Share-0.010.0%-0.060.0%-0.010.0%0.000.0%-0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.010.0%0.000.0%
Usd Total Gains Per Share-0.010.0%-0.060.0%-0.010.0%0.010.0%-0.010.0%
Usd Price Per Share1.03-1.54-3.17-2.73-20.64-
Price to Earnings Ratio-6.83--13.72--19.70-40.03-86.64-
Price-to-Total Gains Ratio-127.12--225.63-122.19-23.31-1,301.26-
Price to Book Ratio2.40-3.37-4.43-4.74-33.19-
Price-to-Total Gains Ratio-127.12--225.63-122.19-23.31-1,301.26-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.5505
Number of shares644
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.060.00
Usd Total Gains Per Share-0.060.01
Gains per Quarter (644 shares)-39.666.92
Gains per Year (644 shares)-158.6227.67
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-159-169181018
20-317-328361946
30-476-487542974
40-634-6467239102
50-793-8059049130
60-952-96410858158
70-1110-112312668186
80-1269-128214478214
90-1428-144116188242
100-1586-160017997270

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%4.08.00.033.3%7.012.00.036.8%10.019.010.025.6%13.019.013.028.9%
Book Value Change Per Share1.03.00.025.0%7.05.00.058.3%11.08.00.057.9%21.018.00.053.8%24.021.00.053.3%
Dividend per Share0.00.04.00.0%2.00.010.016.7%5.00.014.026.3%5.00.034.012.8%5.00.040.011.1%
Total Gains per Share1.03.00.025.0%7.05.00.058.3%12.07.00.063.2%22.017.00.056.4%25.020.00.055.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Cellumed Co. Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---11.540-87.968+662%-14.234+23%5.396-314%-12.038+4%
Book Value Per Share--611.955663.076-8%1027.282-40%735.525-17%781.090-22%
Current Ratio--1.3011.380-6%1.716-24%1.526-15%1.008+29%
Debt To Asset Ratio--0.6110.583+5%0.448+36%0.572+7%0.494+24%
Debt To Equity Ratio--1.5991.480+8%0.815+96%2.069-23%1.370+17%
Dividend Per Share----0%-0%9.950-100%4.848-100%
Enterprise Value--25433938600.00065092329060.000-61%195504581272.500-87%215115319139.333-88%1622665701228.286-98%
Eps---53.724-150.242+180%-98.481+83%-43.088-20%-32.311-40%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--0.1930.611-68%2.031-90%3.214-94%146.810-100%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.744+34%
Market Cap111480507000.000+34%73833816600.000110436163650.000-33%228182730750.000-68%196039868873.684-62%1484157405092.308-95%
Net Profit Margin---0.082-0.275+236%-0.210+156%-0.115+40%-0.212+159%
Operating Margin----0%-0%-0.0170%-0.1510%
Operating Ratio--1.8941.8980%1.752+8%1.330+42%1.411+34%
Pb Ratio3.620+34%2.3973.370-29%4.429-46%4.737-49%33.192-93%
Pe Ratio-10.307-51%-6.827-13.716+101%-19.699+189%40.032-117%86.636-108%
Price Per Share2215.000+34%1467.0002194.250-33%4533.750-68%3895.105-62%29488.641-95%
Price To Free Cash Flow Ratio----1.1290%-25.1990%-17.3450%-63.3210%
Price To Total Gains Ratio-191.934-51%-127.118-225.628+77%122.193-204%23.314-645%1301.256-110%
Quick Ratio---0.330-100%0.840-100%0.911-100%0.688-100%
Return On Assets---0.034-0.110+222%-0.054+57%-0.030-11%-0.025-26%
Return On Equity---0.089-0.316+254%-0.097+8%-0.092+3%-0.065-28%
Total Gains Per Share---11.540-87.968+662%-14.234+23%15.346-175%-7.191-38%
Usd Book Value--21559693.40023360722.102-8%36192019.026-40%25913181.757-17%27518466.549-22%
Usd Book Value Change Per Share---0.008-0.062+662%-0.010+23%0.004-314%-0.008+4%
Usd Book Value Per Share--0.4280.464-8%0.719-40%0.515-17%0.547-22%
Usd Dividend Per Share----0%-0%0.007-100%0.003-100%
Usd Enterprise Value--17803757.02045564630.342-61%136853206.891-87%150580723.398-88%1135865990.860-98%
Usd Eps---0.038-0.105+180%-0.069+83%-0.030-20%-0.023-40%
Usd Free Cash Flow----1278015.7480%-3109039.6230%-1968421.0260%-1086795.3870%
Usd Market Cap78036354.900+34%51683671.62077305314.555-33%159727911.525-68%137227908.212-62%1038910183.565-95%
Usd Price Per Share1.551+34%1.0271.536-33%3.174-68%2.727-62%20.642-95%
Usd Profit---1892726.500-5293151.131+180%-3469555.234+83%-1518031.017-20%-1138355.409-40%
Usd Revenue--23065915.60019576647.204+18%17749417.756+30%17358713.795+33%9794042.875+136%
Usd Total Gains Per Share---0.008-0.062+662%-0.010+23%0.011-175%-0.005-38%
 EOD+4 -3MRQTTM+15 -14YOY+13 -165Y+7 -2410Y+9 -23

3.3 Fundamental Score

Let's check the fundamental score of Cellumed Co. Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.307
Price to Book Ratio (EOD)Between0-13.620
Net Profit Margin (MRQ)Greater than0-0.082
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than11.301
Debt to Asset Ratio (MRQ)Less than10.611
Debt to Equity Ratio (MRQ)Less than11.599
Return on Equity (MRQ)Greater than0.15-0.089
Return on Assets (MRQ)Greater than0.05-0.034
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Cellumed Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.355
Ma 20Greater thanMa 502,188.300
Ma 50Greater thanMa 1002,618.020
Ma 100Greater thanMa 2002,463.190
OpenGreater thanClose2,115.000
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Cellumed Co. Ltd

Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi whole, posterior tibialis, anterior tibialis, semitendinosus, gracilis, and peroneus longus tendons, and meniscus lateral and medial; cancellous bone chips and cortical cancellous dental bone powders; and femoral, tibia, radius, and ulna shafts, femur distal, tibia proximal, and cervical spacer bones. In addition, the company offers medical devices for tissue regeneration, such as Rafugen DBM Gel Pro, Bio BMP2, BIOFIX SCREW, BIO MENISCUS GRAFT, SOLID W6, and viscoseal syringe; and joint reconstruction, comprising luminus flex total knee system fixed and mobile type and luminus flex patient specific instruments. Further, it is involved in biopharmaceutical development; construction machinery; food handling; and sales and brokerage of travel products. The company was formerly known as Korea Bone Bank Co., Ltd. and changed its name to Cellumed Co.,Ltd. in April 2013. Cellumed Co.,Ltd. was founded in 1985 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-12-09 17:19:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Cellumed earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Cellumed to the Medical Instruments & Supplies industry mean.
  • A Net Profit Margin of -8.2% means that ₩-0.08 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cellumed Co. Ltd:

  • The MRQ is -8.2%. The company is making a loss. -1
  • The TTM is -27.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-8.2%TTM-27.5%+19.3%
TTM-27.5%YOY-21.0%-6.5%
TTM-27.5%5Y-11.5%-16.1%
5Y-11.5%10Y-21.2%+9.7%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.2%5.5%-13.7%
TTM-27.5%4.5%-32.0%
YOY-21.0%7.3%-28.3%
5Y-11.5%7.1%-18.6%
10Y-21.2%7.6%-28.8%
4.3.1.2. Return on Assets

Shows how efficient Cellumed is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cellumed to the Medical Instruments & Supplies industry mean.
  • -3.4% Return on Assets means that Cellumed generated ₩-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cellumed Co. Ltd:

  • The MRQ is -3.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.4%TTM-11.0%+7.6%
TTM-11.0%YOY-5.4%-5.6%
TTM-11.0%5Y-3.0%-8.0%
5Y-3.0%10Y-2.5%-0.5%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.4%0.9%-4.3%
TTM-11.0%0.8%-11.8%
YOY-5.4%1.5%-6.9%
5Y-3.0%1.6%-4.6%
10Y-2.5%1.6%-4.1%
4.3.1.3. Return on Equity

Shows how efficient Cellumed is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cellumed to the Medical Instruments & Supplies industry mean.
  • -8.9% Return on Equity means Cellumed generated ₩-0.09 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cellumed Co. Ltd:

  • The MRQ is -8.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -31.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.9%TTM-31.6%+22.7%
TTM-31.6%YOY-9.7%-22.0%
TTM-31.6%5Y-9.2%-22.4%
5Y-9.2%10Y-6.5%-2.8%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.9%2.0%-10.9%
TTM-31.6%1.4%-33.0%
YOY-9.7%2.7%-12.4%
5Y-9.2%3.1%-12.3%
10Y-6.5%3.0%-9.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Cellumed Co. Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Cellumed is operating .

  • Measures how much profit Cellumed makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cellumed to the Medical Instruments & Supplies industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cellumed Co. Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-1.7%+1.7%
5Y-1.7%10Y-15.1%+13.4%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.5%-8.5%
TTM-7.2%-7.2%
YOY-9.9%-9.9%
5Y-1.7%9.6%-11.3%
10Y-15.1%9.4%-24.5%
4.3.2.2. Operating Ratio

Measures how efficient Cellumed is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • An Operation Ratio of 1.89 means that the operating costs are ₩1.89 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Cellumed Co. Ltd:

  • The MRQ is 1.894. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.898. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.894TTM1.898-0.004
TTM1.898YOY1.752+0.146
TTM1.8985Y1.330+0.568
5Y1.33010Y1.411-0.081
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8941.038+0.856
TTM1.8981.056+0.842
YOY1.7521.001+0.751
5Y1.3301.047+0.283
10Y1.4111.008+0.403
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Cellumed Co. Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cellumed is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A Current Ratio of 1.30 means the company has ₩1.30 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Cellumed Co. Ltd:

  • The MRQ is 1.301. The company is just able to pay all its short-term debts.
  • The TTM is 1.380. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.301TTM1.380-0.079
TTM1.380YOY1.716-0.335
TTM1.3805Y1.526-0.145
5Y1.52610Y1.008+0.517
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3012.076-0.775
TTM1.3802.158-0.778
YOY1.7162.521-0.805
5Y1.5262.652-1.126
10Y1.0082.636-1.628
4.4.3.2. Quick Ratio

Measures if Cellumed is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cellumed to the Medical Instruments & Supplies industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₩0.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cellumed Co. Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.330-0.330
TTM0.330YOY0.840-0.509
TTM0.3305Y0.911-0.581
5Y0.91110Y0.688+0.223
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.060-1.060
TTM0.3301.063-0.733
YOY0.8401.229-0.389
5Y0.9111.483-0.572
10Y0.6881.628-0.940
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Cellumed Co. Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Cellumed assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cellumed to Medical Instruments & Supplies industry mean.
  • A Debt to Asset Ratio of 0.61 means that Cellumed assets are financed with 61.1% credit (debt) and the remaining percentage (100% - 61.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cellumed Co. Ltd:

  • The MRQ is 0.611. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.583. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.611TTM0.583+0.028
TTM0.583YOY0.448+0.136
TTM0.5835Y0.572+0.011
5Y0.57210Y0.494+0.078
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6110.378+0.233
TTM0.5830.370+0.213
YOY0.4480.344+0.104
5Y0.5720.366+0.206
10Y0.4940.376+0.118
4.5.4.2. Debt to Equity Ratio

Measures if Cellumed is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cellumed to the Medical Instruments & Supplies industry mean.
  • A Debt to Equity ratio of 159.9% means that company has ₩1.60 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cellumed Co. Ltd:

  • The MRQ is 1.599. The company is just able to pay all its debts with equity.
  • The TTM is 1.480. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.599TTM1.480+0.119
TTM1.480YOY0.815+0.665
TTM1.4805Y2.069-0.589
5Y2.06910Y1.370+0.699
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5990.560+1.039
TTM1.4800.563+0.917
YOY0.8150.525+0.290
5Y2.0690.597+1.472
10Y1.3700.655+0.715
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Cellumed generates.

  • Above 15 is considered overpriced but always compare Cellumed to the Medical Instruments & Supplies industry mean.
  • A PE ratio of -6.83 means the investor is paying ₩-6.83 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cellumed Co. Ltd:

  • The EOD is -10.307. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.827. Based on the earnings, the company is expensive. -2
  • The TTM is -13.716. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.307MRQ-6.827-3.481
MRQ-6.827TTM-13.716+6.889
TTM-13.716YOY-19.699+5.983
TTM-13.7165Y40.032-53.748
5Y40.03210Y86.636-46.604
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD-10.30715.020-25.327
MRQ-6.82715.829-22.656
TTM-13.71615.863-29.579
YOY-19.69919.702-39.401
5Y40.03221.364+18.668
10Y86.63624.063+62.573
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cellumed Co. Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1.129+1.129
TTM-1.129YOY-25.199+24.070
TTM-1.1295Y-17.345+16.216
5Y-17.34510Y-63.321+45.976
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.996-12.996
TTM-1.1299.006-10.135
YOY-25.199-0.157-25.042
5Y-17.3452.951-20.296
10Y-63.321-1.698-61.623
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Cellumed is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A PB ratio of 2.40 means the investor is paying ₩2.40 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Cellumed Co. Ltd:

  • The EOD is 3.620. Based on the equity, the company is fair priced.
  • The MRQ is 2.397. Based on the equity, the company is underpriced. +1
  • The TTM is 3.370. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.620MRQ2.397+1.222
MRQ2.397TTM3.370-0.973
TTM3.370YOY4.429-1.059
TTM3.3705Y4.737-1.366
5Y4.73710Y33.192-28.456
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD3.6202.542+1.078
MRQ2.3972.609-0.212
TTM3.3702.705+0.665
YOY4.4292.785+1.644
5Y4.7373.870+0.867
10Y33.1924.398+28.794
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302023-12-312024-03-312024-06-30
Operating Income  -4,582,7423,631,339-951,403501,856-449,548-92,847-542,3952,291,3051,748,910
Net Interest Income  -322,118124,968-197,150-209,803-406,954-678,650-1,085,6031,153,05667,453



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets79,199,440
Total Liabilities48,399,878
Total Stockholder Equity30,265,018
 As reported
Total Liabilities 48,399,878
Total Stockholder Equity+ 30,265,018
Total Assets = 79,199,440

Assets

Total Assets79,199,440
Total Current Assets57,676,671
Long-term Assets21,522,769
Total Current Assets
Total Current Assets  (as reported)57,676,671
Total Current Assets  (calculated)0
+/- 57,676,671
Long-term Assets
Long-term Assets  (as reported)21,522,769
Long-term Assets  (calculated)0
+/- 21,522,769

Liabilities & Shareholders' Equity

Total Current Liabilities44,332,336
Long-term Liabilities4,067,543
Total Stockholder Equity30,265,018
Total Current Liabilities
Total Current Liabilities  (as reported)44,332,336
Total Current Liabilities  (calculated)0
+/- 44,332,336
Long-term Liabilities
Long-term Liabilities  (as reported)4,067,543
Long-term Liabilities  (calculated)0
+/- 4,067,543
Total Stockholder Equity
Total Stockholder Equity (as reported)30,265,018
Total Stockholder Equity (calculated)0
+/- 30,265,018
Other
Common Stock Shares Outstanding 48,155
Net Invested Capital 30,265,018
Net Working Capital 13,344,335



6.3. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
88,317,834
86,696,107
87,198,526
77,776,461
76,336,726
80,965,597
80,891,668
70,404,486
79,869,087
80,432,429
79,224,680
82,001,944
78,500,938
77,269,293
77,881,770
72,261,386
69,643,339
76,073,681
75,853,964
72,637,951
63,001,265
64,793,572
66,312,283
49,579,067
52,342,970
51,649,678
71,031,512
62,936,654
62,609,934
65,551,866
70,801,157
73,798,492
93,674,075
94,377,801
96,370,427
101,453,237
101,315,349
99,349,860
93,255,932
89,059,951
93,206,663
94,211,613
66,470,630
74,983,496
79,199,440
79,199,44074,983,49666,470,63094,211,61393,206,66389,059,95193,255,93299,349,860101,315,349101,453,23796,370,42794,377,80193,674,07573,798,49270,801,15765,551,86662,609,93462,936,65471,031,51251,649,67852,342,97049,579,06766,312,28364,793,57263,001,26572,637,95175,853,96476,073,68169,643,33972,261,38677,881,77077,269,29378,500,93882,001,94479,224,68080,432,42979,869,08770,404,48680,891,66880,965,59776,336,72677,776,46187,198,52686,696,10788,317,834
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29,861,025
29,324,312
29,938,240
28,180,680
29,985,807
30,507,757
22,832,990
20,796,376
23,010,696
41,078,603
40,402,763
41,912,935
43,790,666
48,369,988
50,658,020
72,461,182
72,844,944
73,358,244
74,924,874
66,125,464
67,729,844
65,553,834
56,555,346
59,437,806
61,112,799
50,057,098
58,670,095
57,676,671
57,676,67158,670,09550,057,09861,112,79959,437,80656,555,34665,553,83467,729,84466,125,46474,924,87473,358,24472,844,94472,461,18250,658,02048,369,98843,790,66641,912,93540,402,76341,078,60323,010,69620,796,37622,832,99030,507,75729,985,80728,180,68029,938,24029,324,31229,861,02500000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,002,810
2,361,240
2,092,990
2,515,198
9,641,329
10,108,144
8,056,852
6,833,066
10,764,260
20,364,806
14,666,491
11,985,731
13,926,292
19,239,792
19,161,181
34,565,877
21,720,734
0
872
3,930
1,321
10,008,688
687
531
4,521,263
6,234,894
11,587,984
0
011,587,9846,234,8944,521,26353168710,008,6881,3213,930872021,720,73434,565,87719,161,18119,239,79213,926,29211,985,73114,666,49120,364,80610,764,2606,833,0668,056,85210,108,1449,641,3292,515,1982,092,9902,361,2404,002,81000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,855,010
670,010
231,000
405,932
121,587
1
126,586
133,433
133,432
133,433
0
0
3,423,050
3,686,480
2,760,343
2,169,234
5,063,089
4,358,783
1,259,793
157,132
145,947
153,241
173,450
191,712
1,463,692
619,537
836,631
0
0836,631619,5371,463,692191,712173,450153,241145,947157,1321,259,7934,358,7835,063,0892,169,2342,760,3433,686,4803,423,05000133,433133,432133,433126,5861121,587405,932231,000670,0101,855,01000000000000000000
       Net Receivables 
20,309,889
19,593,920
18,002,196
23,790,804
24,135,818
26,284,082
26,462,806
15,327,822
15,119,644
16,120,271
12,923,533
13,642,331
16,256,496
9,607,454
9,895,884
7,087,819
8,672,658
12,002,737
14,132,121
17,120,809
15,187,426
7,932,342
7,147,798
8,306,021
7,154,395
6,862,265
5,507,517
12,855,434
17,277,504
17,422,791
20,461,352
23,274,742
23,614,878
30,758,722
20,836,705
24,483,910
24,248,184
24,163,356
23,823,340
18,525,991
17,562,174
16,862,860
17,073,262
16,265,871
0
016,265,87117,073,26216,862,86017,562,17418,525,99123,823,34024,163,35624,248,18424,483,91020,836,70530,758,72223,614,87823,274,74220,461,35217,422,79117,277,50412,855,4345,507,5176,862,2657,154,3958,306,0217,147,7987,932,34215,187,42617,120,80914,132,12112,002,7378,672,6587,087,8199,895,8849,607,45416,256,49613,642,33112,923,53316,120,27115,119,64415,327,82226,462,80626,284,08224,135,81823,790,80418,002,19619,593,92020,309,889
       Other Current Assets 
8,050,235
8,096,307
9,231,295
1,564,539
1,555,201
2,074,265
2,543,807
1,169,355
2,004,456
2,358,100
5,050,831
1,549,797
1,730,095
1,924,338
1,858,588
645,996
816,610
692,899
808,113
644,621
1,132,535
335,732
141,321
220,461
491,713
625,666
9,759,293
1,475,516
6,466,939
5,252,466
1,449,285
1,229,077
7,571,010
10,832,978
355,398
386,290
395,367
2,172,234
3,044,222
1,295,473
1,841,490
137,055
153,840
130,922
0
0130,922153,840137,0551,841,4901,295,4733,044,2222,172,234395,367386,290355,39810,832,9787,571,0101,229,0771,449,2855,252,4666,466,9391,475,5169,759,293625,666491,713220,461141,321335,7321,132,535644,621808,113692,899816,610645,9961,858,5881,924,3381,730,0951,549,7975,050,8312,358,1002,004,4561,169,3552,543,8072,074,2651,555,2011,564,5399,231,2958,096,3078,050,235
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,702,098
32,504,604
33,768,857
33,098,814
16,413,532
16,313,401
21,522,769
21,522,76916,313,40116,413,53233,098,81433,768,85732,504,60427,702,09800000000000000000000000000000000000000
       Property Plant Equipment 
10,162,839
9,791,572
9,563,270
9,013,463
8,549,853
8,304,990
8,065,934
8,162,334
8,302,368
8,095,393
7,630,122
8,711,693
8,619,962
8,327,135
8,006,406
7,941,820
7,500,235
7,132,733
7,072,199
7,116,251
6,736,381
6,045,930
6,015,430
6,354,151
6,124,624
6,560,780
6,691,044
5,365,610
5,613,029
5,440,601
5,367,720
5,319,851
5,733,289
7,048,238
8,496,474
9,405,066
9,384,112
9,289,052
9,586,305
10,054,319
12,246,006
12,507,982
5,208,198
5,381,533
0
05,381,5335,208,19812,507,98212,246,00610,054,3199,586,3059,289,0529,384,1129,405,0668,496,4747,048,2385,733,2895,319,8515,367,7205,440,6015,613,0295,365,6106,691,0446,560,7806,124,6246,354,1516,015,4306,045,9306,736,3817,116,2517,072,1997,132,7337,500,2357,941,8208,006,4068,327,1358,619,9628,711,6937,630,1228,095,3938,302,3688,162,3348,065,9348,304,9908,549,8539,013,4639,563,2709,791,57210,162,839
       Goodwill 
4,821,658
4,592,144
4,597,131
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,626,581
851,851
851,851
0
0
0
0
0
0
1,877,204
1,159,044
1,159,044
1,877,204
1,877,204
1,159,044
1,159,044
1,159,044
1,159,044
1,159,044
1,159,044
691,237
691,237
786,517
736,798
45,561
45,561
0
045,56145,561736,798786,517691,237691,2371,159,0441,159,0441,159,0441,159,0441,159,0441,159,0441,877,2041,877,2041,159,0441,159,0441,877,204000000851,851851,8511,626,5810000000000000004,597,1314,592,1444,821,658
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,492,981
7,525,254
6,061,553
5,443,042
10,222,457
12,209,056
8,336,649
12,251,883
10,338,457
12,321,579
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000012,321,57910,338,45712,251,8838,336,64912,209,05610,222,4575,443,0426,061,5537,525,2547,492,98100000000000000000
       Intangible Assets 
5,212,558
4,967,133
4,988,439
361,071
346,234
350,322
392,457
545,161
520,602
547,888
749,314
736,906
722,444
768,064
745,402
738,433
711,973
4,766,459
6,355,985
6,262,724
6,192,072
4,520,015
4,483,736
4,215,435
4,744,970
4,722,988
4,701,588
1,641,808
1,512,395
1,372,378
1,286,765
1,201,658
1,118,094
1,039,331
946,331
868,812
5,162,750
5,963,521
5,801,283
6,816,309
7,849,152
7,711,880
2,828,011
2,762,483
0
02,762,4832,828,0117,711,8807,849,1526,816,3095,801,2835,963,5215,162,750868,812946,3311,039,3311,118,0941,201,6581,286,7651,372,3781,512,3951,641,8084,701,5884,722,9884,744,9704,215,4354,483,7364,520,0156,192,0726,262,7246,355,9854,766,459711,973738,433745,402768,064722,444736,906749,314547,888520,602545,161392,457350,322346,234361,0714,988,4394,967,1335,212,558
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000
> Total Liabilities 
38,974,562
35,577,018
36,225,122
28,573,764
28,175,092
26,536,844
25,324,939
26,391,765
32,314,121
35,772,428
33,419,069
40,732,579
29,642,350
31,401,709
31,818,107
25,238,285
25,465,289
32,314,071
32,106,730
30,462,094
27,702,508
26,380,801
24,925,338
26,562,711
26,826,734
26,009,906
49,619,159
58,800,164
48,756,024
45,973,532
42,700,427
32,607,705
52,768,068
50,322,472
48,382,293
50,993,660
49,940,587
45,785,689
39,311,163
38,266,468
44,697,549
45,919,424
43,452,930
43,603,107
48,399,878
48,399,87843,603,10743,452,93045,919,42444,697,54938,266,46839,311,16345,785,68949,940,58750,993,66048,382,29350,322,47252,768,06832,607,70542,700,42745,973,53248,756,02458,800,16449,619,15926,009,90626,826,73426,562,71124,925,33826,380,80127,702,50830,462,09432,106,73032,314,07125,465,28925,238,28531,818,10731,401,70929,642,35040,732,57933,419,06935,772,42832,314,12126,391,76525,324,93926,536,84428,175,09228,573,76436,225,12235,577,01838,974,562
   > Total Current Liabilities 
26,856,739
28,109,509
34,093,366
26,351,123
26,013,618
23,864,763
22,990,264
24,000,349
29,748,042
32,769,376
31,692,067
39,020,328
27,859,661
29,572,320
29,947,972
23,222,305
23,323,993
30,174,590
29,629,860
26,369,162
23,497,984
22,353,400
20,840,915
22,298,173
22,482,481
18,210,155
37,154,386
43,774,952
33,169,311
29,850,285
26,071,009
26,479,555
47,196,537
44,400,018
42,815,584
44,741,588
43,804,225
39,693,102
33,898,463
33,061,855
39,296,168
41,561,484
39,462,966
39,600,150
44,332,336
44,332,33639,600,15039,462,96641,561,48439,296,16833,061,85533,898,46339,693,10243,804,22544,741,58842,815,58444,400,01847,196,53726,479,55526,071,00929,850,28533,169,31143,774,95237,154,38618,210,15522,482,48122,298,17320,840,91522,353,40023,497,98426,369,16229,629,86030,174,59023,323,99323,222,30529,947,97229,572,32027,859,66139,020,32831,692,06732,769,37629,748,04224,000,34922,990,26423,864,76326,013,61826,351,12334,093,36628,109,50926,856,739
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,899,848
11,073,288
7,759,191
14,887,092
14,865,879
0
8,160,607
8,423,013
0
7,083,364
6,080,000
4,746,720
4,746,640
4,580,000
4,580,000
5,080,000
3,580,000
2,180,000
4,180,000
4,180,000
4,180,000
5,720,000
6,420,000
5,773,000
0
0
0
0
00005,773,0006,420,0005,720,0004,180,0004,180,0004,180,0002,180,0003,580,0005,080,0004,580,0004,580,0004,746,6404,746,7206,080,0007,083,36408,423,0138,160,607014,865,87914,887,0927,759,19111,073,28818,899,84800000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,899,848
11,073,288
7,759,191
14,887,092
14,865,879
0
8,160,607
8,423,013
0
7,083,364
0
0
0
0
0
0
0
0
0
0
0
10,335,089
9,891,686
11,023,055
12,314,013
14,358,599
10,796,950
0
010,796,95014,358,59912,314,01311,023,0559,891,68610,335,089000000000007,083,36408,423,0138,160,607014,865,87914,887,0927,759,19111,073,28818,899,84800000000000000000
       Accounts payable 
3,076,037
1,464,032
1,621,921
1,572,564
1,492,561
1,957,131
1,202,073
1,462,429
1,473,792
1,116,800
1,283,222
1,432,447
1,270,453
1,794,721
2,088,820
1,562,102
1,223,131
1,024,070
1,486,823
1,951,865
1,849,624
1,124,356
708,484
1,164,179
1,318,759
904,982
947,378
0
4,983,514
4,380,527
5,211,795
5,892,389
7,369,067
8,666,977
0
0
0
0
5,481,333
5,906,067
7,656,084
8,287,456
6,414,496
6,822,940
0
06,822,9406,414,4968,287,4567,656,0845,906,0675,481,33300008,666,9777,369,0675,892,3895,211,7954,380,5274,983,5140947,378904,9821,318,7591,164,179708,4841,124,3561,849,6241,951,8651,486,8231,024,0701,223,1311,562,1022,088,8201,794,7211,270,4531,432,4471,283,2221,116,8001,473,7921,462,4291,202,0731,957,1311,492,5611,572,5641,621,9211,464,0323,076,037
       Other Current Liabilities 
14,554,314
13,567,190
13,099,373
5,134,294
5,525,070
6,884,769
4,331,962
5,876,084
5,800,215
5,071,477
4,776,818
12,758,277
8,569,960
11,492,699
11,769,263
8,240,939
7,670,627
10,250,672
8,543,708
8,024,736
6,761,268
5,438,397
4,845,065
6,416,396
6,469,688
4,769,506
24,161,953
0
18,881,232
16,665,572
14,464,818
15,027,155
24,530,845
21,496,772
0
0
0
0
-1
-1
0
0
56,190
-3
0
0-356,19000-1-1000021,496,77224,530,84515,027,15514,464,81816,665,57218,881,232024,161,9534,769,5066,469,6886,416,3964,845,0655,438,3976,761,2688,024,7368,543,70810,250,6727,670,6278,240,93911,769,26311,492,6998,569,96012,758,2774,776,8185,071,4775,800,2155,876,0844,331,9626,884,7695,525,0705,134,29413,099,37313,567,19014,554,314
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,228,115
4,065,069
4,378,516
4,357,940
3,989,963
4,002,957
4,067,543
4,067,5434,002,9573,989,9634,357,9404,378,5164,065,0694,228,11500000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,158,569
1,082,856
1,546,995
1,112,637
1,176,080
1,067,371
1,189,469
1,075,291
1,035,255
564,782
443,063
604,544
0
0
0
0
0000604,544443,063564,7821,035,2551,075,2911,189,4691,067,3711,176,0801,112,6371,546,9951,082,8561,158,56900000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-18,899,848
-11,073,288
-7,759,191
-14,887,092
-14,865,879
0
-8,160,607
-8,423,013
0
-7,083,364
-6,080,000
-4,746,720
-4,746,640
-4,580,000
-4,580,000
-5,080,000
-3,580,000
-2,180,000
-4,180,000
-4,180,000
-4,180,000
-4,677,337
-5,589,751
-4,569,820
1,179,478
1,154,184
1,008,456
0
01,008,4561,154,1841,179,478-4,569,820-5,589,751-4,677,337-4,180,000-4,180,000-4,180,000-2,180,000-3,580,000-5,080,000-4,580,000-4,580,000-4,746,640-4,746,720-6,080,000-7,083,3640-8,423,013-8,160,6070-14,865,879-14,887,092-7,759,191-11,073,288-18,899,84800000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
1
0
0
-1
0
0-1001-1000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,518,974
17,479,719
15,337,969
15,231,810
7,579,442
7,731,349
4,717,977
4,832,109
4,237,820
4,269,596
0
951,962
912,134
872,306
832,478
792,650
752,822
0
0
0
0
0
0
0
0
0
0
0
00000000000752,822792,650832,478872,306912,134951,96204,269,5964,237,8204,832,1094,717,9777,731,3497,579,44215,231,81015,337,96917,479,71917,518,97400000000000000000
> Total Stockholder Equity
49,538,955
51,214,535
51,174,503
49,641,757
48,583,619
54,939,571
56,004,816
44,853,813
48,418,485
45,487,617
46,529,530
42,635,166
50,238,567
47,254,363
47,591,695
49,030,866
46,204,141
45,827,566
45,898,598
44,937,824
38,101,225
41,220,305
44,191,703
26,389,039
28,826,591
25,639,772
21,412,353
4,136,490
13,853,910
19,578,334
28,100,731
41,190,788
40,906,007
44,055,329
47,988,134
50,459,577
51,374,762
53,564,171
53,944,769
50,793,483
48,509,115
47,272,805
22,461,292
30,828,120
30,265,018
30,265,01830,828,12022,461,29247,272,80548,509,11550,793,48353,944,76953,564,17151,374,76250,459,57747,988,13444,055,32940,906,00741,190,78828,100,73119,578,33413,853,9104,136,49021,412,35325,639,77228,826,59126,389,03944,191,70341,220,30538,101,22544,937,82445,898,59845,827,56646,204,14149,030,86647,591,69547,254,36350,238,56742,635,16646,529,53045,487,61748,418,48544,853,81356,004,81654,939,57148,583,61949,641,75751,174,50351,214,53549,538,955
   Common Stock
61,603,956
62,844,555
62,844,555
63,600,983
63,600,983
68,055,940
68,987,038
71,683,490
71,683,490
72,068,698
75,480,763
77,575,113
84,034,073
86,512,571
87,854,846
90,776,923
90,776,923
9,077,692
9,184,074
9,416,719
9,626,749
10,154,951
10,214,006
10,214,006
10,214,006
10,300,937
10,365,966
12,167,750
14,850,529
16,260,741
17,260,741
19,746,453
19,803,487
19,803,487
19,803,487
19,803,487
19,803,487
20,112,087
20,888,215
21,094,822
21,402,363
0
0
0
0
000021,402,36321,094,82220,888,21520,112,08719,803,48719,803,48719,803,48719,803,48719,803,48719,746,45317,260,74116,260,74114,850,52912,167,75010,365,96610,300,93710,214,00610,214,00610,214,00610,154,9519,626,7499,416,7199,184,0749,077,69290,776,92390,776,92387,854,84686,512,57184,034,07377,575,11375,480,76372,068,69871,683,49071,683,49068,987,03868,055,94063,600,98363,600,98362,844,55562,844,55561,603,956
   Retained Earnings Total Equity000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
76,991,273
84,755,843
88,893,252
93,245,125
103,767,340
104,524,272
104,524,272
104,524,272
104,524,272
104,524,272
107,148,765
114,294,364
116,421,035
120,176,074
0
0
0
0
0000120,176,074116,421,035114,294,364107,148,765104,524,272104,524,272104,524,272104,524,272104,524,272103,767,34093,245,12588,893,25284,755,84376,991,273000000000000000000000000000
   Treasury Stock00000000000-9,277-9,277-9,277-9,277-9,277-9,277-9,2770000-9,277-9,276-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,277-9,2770
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,644,565
1,612,385
1,686,745
1,517,735
-2,511,807
-536,044
-5,351,217
-1,313,151
-3,056,351
-5,913,230
-13,070,997
-11,027,306
-11,027,306
-8,460,125
1,836,950
1,705,901
1,925,380
-13,070,997
-13,070,997
-13,070,997
-13,070,997
-13,070,997
-13,070,997
-13,070,997
0
0
0
0
0000-13,070,997-13,070,997-13,070,997-13,070,997-13,070,997-13,070,997-13,070,9971,925,3801,705,9011,836,950-8,460,125-11,027,306-11,027,306-13,070,997-5,913,230-3,056,351-1,313,151-5,351,217-536,044-2,511,8071,517,7351,686,7451,612,3851,644,56500000000000000000



6.4. Balance Sheets

Currency in KRW. All numbers in thousands.




6.5. Cash Flows

Currency in KRW. All numbers in thousands.




6.6. Income Statements

Currency in KRW. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue95,552,960
Cost of Revenue-89,920,889
Gross Profit5,632,0715,632,071
 
Operating Income (+$)
Gross Profit5,632,071
Operating Expense-106,292,607
Operating Income-10,739,648-100,660,536
 
Operating Expense (+$)
Research Development1,505,675
Selling General Administrative5,437,968
Selling And Marketing Expenses0
Operating Expense106,292,6076,943,643
 
Net Interest Income (+$)
Interest Income731,365
Interest Expense-1,673,263
Other Finance Cost-0
Net Interest Income-941,899
 
Pretax Income (+$)
Operating Income-10,739,648
Net Interest Income-941,899
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-38,581,046-10,739,648
EBIT - interestExpense = -1,673,263
-37,297,756
-35,624,493
Interest Expense1,673,263
Earnings Before Interest and Taxes (EBIT)0-36,907,782
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-38,581,046
Tax Provision--654,126
Net Income From Continuing Ops-37,926,919-37,926,919
Net Income-37,297,756
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0941,899
 

Technical Analysis of Cellumed
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cellumed. The general trend of Cellumed is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cellumed's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cellumed Co. Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2,840 < 2,880 < 3,385.

The bearish price targets are: 1,969 > 1,946 > 1,922.

Tweet this
Cellumed Co. Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cellumed Co. Ltd. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cellumed Co. Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cellumed Co. Ltd. The current macd is -102.33497507.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cellumed price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cellumed. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cellumed price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cellumed Co. Ltd Daily Moving Average Convergence/Divergence (MACD) ChartCellumed Co. Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cellumed Co. Ltd. The current adx is 15.60.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cellumed shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Cellumed Co. Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cellumed Co. Ltd. The current sar is 1,939.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cellumed Co. Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cellumed Co. Ltd. The current rsi is 46.36. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Cellumed Co. Ltd Daily Relative Strength Index (RSI) ChartCellumed Co. Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cellumed Co. Ltd. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cellumed price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cellumed Co. Ltd Daily Stochastic Oscillator ChartCellumed Co. Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cellumed Co. Ltd. The current cci is 21.06.

Cellumed Co. Ltd Daily Commodity Channel Index (CCI) ChartCellumed Co. Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cellumed Co. Ltd. The current cmo is 2.42176649.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cellumed Co. Ltd Daily Chande Momentum Oscillator (CMO) ChartCellumed Co. Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cellumed Co. Ltd. The current willr is -38.0859375.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cellumed is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cellumed Co. Ltd Daily Williams %R ChartCellumed Co. Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cellumed Co. Ltd.

Cellumed Co. Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cellumed Co. Ltd. The current atr is 177.71.

Cellumed Co. Ltd Daily Average True Range (ATR) ChartCellumed Co. Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cellumed Co. Ltd. The current obv is 338,532,889.

Cellumed Co. Ltd Daily On-Balance Volume (OBV) ChartCellumed Co. Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cellumed Co. Ltd. The current mfi is 60.85.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Cellumed Co. Ltd Daily Money Flow Index (MFI) ChartCellumed Co. Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cellumed Co. Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Cellumed Co. Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cellumed Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.355
Ma 20Greater thanMa 502,188.300
Ma 50Greater thanMa 1002,618.020
Ma 100Greater thanMa 2002,463.190
OpenGreater thanClose2,115.000
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cellumed with someone you think should read this too:
  • Are you bullish or bearish on Cellumed? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cellumed? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cellumed Co. Ltd

I send you an email if I find something interesting about Cellumed Co. Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Cellumed Co. Ltd.

Receive notifications about Cellumed Co. Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.